Key Takeaways MRK to acquire Verona Pharma for $10B, adding FDA-approved COPD drug Ohtuvayre to its portfolio. Ohtuvayre offers dual PDE3/4 inhibition, combining bronchodilation and anti-inflammatory effects. The deal supports MRK's diversification as Keytruda faces patent expiry and increased competition. Earlier this week, Merck (MRK) announced a definitive agreement to acquire Verona Pharma (VRNA) for approximately$10 billion. The deal will add Verona’s Ohtuvayre, approved for the maintenance treatmen ...